Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials

Bibliographic Details
Main Author: Pazan, F
Publication Date: 2020
Other Authors: Petrovic, M, Cherubini, A, Onder, G, Cruz-Jentoft, A, Denkinger, M, van der Cammen, T, Stevenson, J, Ibrahim, K, Rajkumar, C, Bakken, M, Baeyens, JP, Crome, P, Frühwald, T, Gallaghar, P, Guðmundsson, A, Knol, W, O’Mahony, D, Pilotto, A, Rönnemaa, E, Serra-Rexach, JA, Soulis, G, van Marum, R, Ziere, G, Mair, A, Burkhardt, H, Neumann-Podczaska, A, Wieczorowska-Tobis, K, Fernandes, MA, Gruner, H, Dallmeier, D, Beuscart, J, van der Velde, N, Wehling, M
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.17/4495
Summary: Background: Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty; however, a causal relation has not been proven in older people with clinically manifest frailty. Methods: A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial aspects of frailty that were published from January 1998 to October 2019. Results: Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimensional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recombinant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty. Conclusion: So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally consistent and thus reproducible concept of frailty assessment.
id RCAP_cb9d35e1d576ff07333692fc3b10647b
oai_identifier_str oai:repositorio.chlc.pt:10400.17/4495
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled TrialsHCC MEDAgedHumansFrail ElderlyFrailty / drug therapy*PolypharmacyRandomized Controlled Trials as TopicBackground: Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty; however, a causal relation has not been proven in older people with clinically manifest frailty. Methods: A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial aspects of frailty that were published from January 1998 to October 2019. Results: Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimensional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recombinant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty. Conclusion: So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally consistent and thus reproducible concept of frailty assessment.SpringerRepositório da Unidade Local de Saúde São JoséPazan, FPetrovic, MCherubini, AOnder, GCruz-Jentoft, ADenkinger, Mvan der Cammen, TStevenson, JIbrahim, KRajkumar, CBakken, MBaeyens, JPCrome, PFrühwald, TGallaghar, PGuðmundsson, AKnol, WO’Mahony, DPilotto, ARönnemaa, ESerra-Rexach, JASoulis, Gvan Marum, RZiere, GMair, ABurkhardt, HNeumann-Podczaska, AWieczorowska-Tobis, KFernandes, MAGruner, HDallmeier, DBeuscart, Jvan der Velde, NWehling, M2023-04-14T13:35:49Z2020-012020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4495eng10.1007/s00228-020-02951-8info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-06T16:48:21Zoai:repositorio.chlc.pt:10400.17/4495Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T00:19:41.012845Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
title Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
spellingShingle Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
Pazan, F
HCC MED
Aged
Humans
Frail Elderly
Frailty / drug therapy*
Polypharmacy
Randomized Controlled Trials as Topic
title_short Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
title_full Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
title_fullStr Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
title_full_unstemmed Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
title_sort Current Evidence on the Impact of Medication Optimization or Pharmacological Interventions on Frailty or Aspects of Frailty: a Systematic Review of Randomized Controlled Trials
author Pazan, F
author_facet Pazan, F
Petrovic, M
Cherubini, A
Onder, G
Cruz-Jentoft, A
Denkinger, M
van der Cammen, T
Stevenson, J
Ibrahim, K
Rajkumar, C
Bakken, M
Baeyens, JP
Crome, P
Frühwald, T
Gallaghar, P
Guðmundsson, A
Knol, W
O’Mahony, D
Pilotto, A
Rönnemaa, E
Serra-Rexach, JA
Soulis, G
van Marum, R
Ziere, G
Mair, A
Burkhardt, H
Neumann-Podczaska, A
Wieczorowska-Tobis, K
Fernandes, MA
Gruner, H
Dallmeier, D
Beuscart, J
van der Velde, N
Wehling, M
author_role author
author2 Petrovic, M
Cherubini, A
Onder, G
Cruz-Jentoft, A
Denkinger, M
van der Cammen, T
Stevenson, J
Ibrahim, K
Rajkumar, C
Bakken, M
Baeyens, JP
Crome, P
Frühwald, T
Gallaghar, P
Guðmundsson, A
Knol, W
O’Mahony, D
Pilotto, A
Rönnemaa, E
Serra-Rexach, JA
Soulis, G
van Marum, R
Ziere, G
Mair, A
Burkhardt, H
Neumann-Podczaska, A
Wieczorowska-Tobis, K
Fernandes, MA
Gruner, H
Dallmeier, D
Beuscart, J
van der Velde, N
Wehling, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Unidade Local de Saúde São José
dc.contributor.author.fl_str_mv Pazan, F
Petrovic, M
Cherubini, A
Onder, G
Cruz-Jentoft, A
Denkinger, M
van der Cammen, T
Stevenson, J
Ibrahim, K
Rajkumar, C
Bakken, M
Baeyens, JP
Crome, P
Frühwald, T
Gallaghar, P
Guðmundsson, A
Knol, W
O’Mahony, D
Pilotto, A
Rönnemaa, E
Serra-Rexach, JA
Soulis, G
van Marum, R
Ziere, G
Mair, A
Burkhardt, H
Neumann-Podczaska, A
Wieczorowska-Tobis, K
Fernandes, MA
Gruner, H
Dallmeier, D
Beuscart, J
van der Velde, N
Wehling, M
dc.subject.por.fl_str_mv HCC MED
Aged
Humans
Frail Elderly
Frailty / drug therapy*
Polypharmacy
Randomized Controlled Trials as Topic
topic HCC MED
Aged
Humans
Frail Elderly
Frailty / drug therapy*
Polypharmacy
Randomized Controlled Trials as Topic
description Background: Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty; however, a causal relation has not been proven in older people with clinically manifest frailty. Methods: A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial aspects of frailty that were published from January 1998 to October 2019. Results: Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimensional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recombinant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty. Conclusion: So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally consistent and thus reproducible concept of frailty assessment.
publishDate 2020
dc.date.none.fl_str_mv 2020-01
2020-01-01T00:00:00Z
2023-04-14T13:35:49Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4495
url http://hdl.handle.net/10400.17/4495
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1007/s00228-020-02951-8
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833600487614578688